ArticleBMC microbiology2024
Susceptibility of various Gram-negative bacteria to antibacterial agents: SMART in China 2019-2020.
Article in BMC microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Deciphering the Implications ofPathogens (Basel, Switzerland) · 2026Review
- Characteristics of the resistome and the potential for bloodstream infections in patients with gut colonization byFrontiers in cellular and infection microbiology · 2026Article
- Ceftolozane/Tazobactam Susceptibility in ESBL-Producing Enterobacterales: Insights from the SMART Program 2020-2022 in China.Infection and drug resistance · 2026Article
- Current and future options for the treatment of serious infections due to carbapenem-resistantClinical microbiology reviews · 2025Review
- Type I-E* CRISPR-Cas ofmSphere · 2025Article
- Exploring the relationship between employee engagement and counterproductive work behaviour.Frontiers in psychology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Study for Monitoring Antimicrobial Resistance Trends (SMART) is an international surveillance program longitudinally monitoring aerobic and facultative Gram-negative bacteria (GNB) involvement in infections and their antimicrobial resistance profiles. Here the incidence and resistance patterns of Chinese GNB isolates from bloodstream infections (BSI), intraabdominal infections (IAI), respiratory tract infections (RTI) and urinary tract infections (UTI) to commonly used antibacterial agents has been updated. 4,975 GNB isolates collected from 22 hospitals across 7 regions of China from 2019 to 2020 were analyzed. Antimicrobial minimum inhibitory concentrations were assessed using broth microdilution, and susceptibility interpretations followed the breakpoints of European Committee on Antimicrobial Susceptibility Testing 2022 or Clinical and Laboratory Standards Institute.
resultsThis study affirmed that Escherichia coli (Ec) was the most commonly identified GNB (32.1%) and then Klebsiella pneumoniae (Kp) (25.3%), Pseudomonas aeruginosa (Pa) (13.9%) and Acinetobacter baumannii (10.5%). The detection rates of carbapenem-resistant (CR) Enterobacterales varied across major infection sites, ranging from 10.3% in UTI to 18.9% in RTI. Specifically, the detection rates of CR-Kp and CR-Pa ranged from 16.2% in IAI to 35.8% in UTI and from 16.1% in UTI to 38.0% in RTI, respectively. Extended-spectrum β-lactamases (ESBL)-producing Ec and Kp bacteria exhibited over 91.7% susceptibility to carbapenems and at least 87.8% susceptibility to amikacin and colistin, but showed lower susceptibility to piperacillin/tazobactam (57.5-86.2%), levofloxacin (10.8-39.7%) and aztreonam (15.3-27.6%) across different infection sources. Amikacin showed higher efficacy against CR strains compared to other commonly used antibacterial drugs, with 80.0% susceptibility against CR-Ec and 82.3% susceptibility against CR-Pa, while only 36.3% susceptibility was observed against CR-Kp.
conclusionsThe study found varying incidences of CR isolates in Chinese hospitals. Treatment options remained limited due to resistance to multiple antibacterial agents. Carbapenems demonstrated effective antimicrobial in vitro activity against ESBL-producing Enterobacterales found in BSI, IAI, UTI and RTI, outperforming broad-spectrum cephalosporins and other β-lactamase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.